Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Gastroenterology. 2008 May 7;135(2):552–567. doi: 10.1053/j.gastro.2008.04.037

Figure 3. TL1A synergizes with IL-12 or IL-23 in the development of a TH1 or TH17 response during chronic colitis.

Figure 3

Figure 3

Figure 3

Figure 3

Figure 3

Figure 3

CD4+ T cells from GALT of untreated or DSS-treated mice were cultured with IL-12 or IL-23 with or without the additsion of TL1A (10 ng/ml) for 72 h. (A) IFN-γ and IL-17 production were measured by ELISA (n=5 per group). Data presented are means ± SD. (B) FACS analysis of intracellular IFN-γ and IL-17 production by CD4+ T cell isolated from the LP of DSS-treated mice. One representative experiment out of 3 independent experiments is shown. (C) IFN-γ and IL-17 production in LP of DSS-treated mice was measured by ELISA (n=5 per group). (D) IL-6 production from GALT stimulated with or without anti-CD3ε and anti-CD28 was measured by ELISA. (E) IL-6 production from GALT CD4+ T cells stimulated with or without TL1A. (F) IL-6 production from GALT CD4+ T cells of DSS-treated mice stimulated with IL-12 or IL-23 with or without the addition of TL1A.